SCHEMBL2533397

SCHEMBL2533397

CCOC(=O)CCN(Cc1ccc2nc(N)n(Cc3nc(C)ccc3O)c2c1)c1cccc(C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.33
▸ F10 P00742 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TLR8 Q9NR97 1/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ CDK4 P11802 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ ASAH1 Q13510 1/20 0.32
▸ F2R P25116 1/20 0.32
▸ AR P10275 1/20 0.32
▸ PTGDR2 Q9Y5Y4 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ DHFR P00374 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540106 0.91 ASAH1 (0.35) F2MAPTCDK1CDK4CDK2
SCHEMBL2541401 0.89 TLR8 (0.38) MAPTKDM4ETLR8CDK1CDK4
SCHEMBL2541966 0.87 SOS1 (0.35) MAPTKDM4ETLR8CDK1CDK4
Hydrochloric Acid SCHEMBL2539558 0.86 SOS1 (0.36) MAPTKDM4EHPGDTLR8CDK1
SCHEMBL2537125 0.83 CDK1 (0.33) MAPTCDK1CDK4CDK2F2R
SCHEMBL2537988 0.77 SOS1 (0.33) MAPTKMT2ASOS1LMNA
SCHEMBL2541947 0.76 MEN1 (0.32) MAPTKDM4EHPGDMEN1ALDH1A1
SCHEMBL8284700 0.73 CA12 (0.45) MAPTKDM4ECDK1CDK4CDK2
SCHEMBL2537168 0.73 MAPT (0.46) MAPTKDM4EHPGDTLR8ASAH1
SCHEMBL8284695 0.73 KDM4E (0.46) KDM4EHPGDTLR8ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 — — US disclosed
EP-1697343-B1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2009-07-01 — — EP disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 F2 3614/4885F10 3861/4885MAPT 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback